Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mensa

Showing results (211-220 of 253) with videos related to

Pageof 26
Sort By:
The Journal of Infection|January 24, 2018
Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysisC De la Calle, H G Ternavasio-de la Vega, L Morata, et al.
European Journal of Gastroenterology & Hepatology|May 4, 2016
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b studyStefan Zeuzem, Parvez Mantry, Vicente Soriano, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|October 24, 2013
Acquisition of resistant microorganisms and infections in HIV-infected patients admitted to the ICUN Cobos-Trigueros, M Rinaudo, M Solé, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 11, 2018
Current time-to-positivity of blood cultures in febrile neutropenia: a tool to be used in stewardship de-escalation strategiesP Puerta-Alcalde, C Cardozo, M Suárez-Lledó, et al.
Drug and Alcohol Dependence|December 12, 2018
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studiesGraham R Foster, Gregory J Dore, Stanley Wang, et al.
Gastroenterology|July 27, 2016
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated CirrhosisEdward Gane, Fred Poordad, Stanley Wang, et al.
Archivos De Bronconeumologia|June 12, 2003
[Second consensus report on the use of antimicrobial agents in exacerbations of chronic obstructive pulmonary disease]F Alvarez, E Bouza, J A García-Rodríguez, et al.
The Lancet. Gastroenterology & Hepatology|November 6, 2018
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trialTarik Asselah, Samuel S Lee, Betty B Yao, et al.
The New England Journal of Medicine|October 12, 2017
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal ImpairmentEdward Gane, Eric Lawitz, David Pugatch, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 11, 2019
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infectionEric Lawitz, Robert Flisiak, Manal Abunimeh, et al.
Pageof 26

Showing results (211-220 of 253) with videos related to

Sort By:
Pageof 26
The Journal of Infection|January 24, 2018
Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysisC De la Calle, H G Ternavasio-de la Vega, L Morata, et al.
European Journal of Gastroenterology & Hepatology|May 4, 2016
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b studyStefan Zeuzem, Parvez Mantry, Vicente Soriano, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|October 24, 2013
Acquisition of resistant microorganisms and infections in HIV-infected patients admitted to the ICUN Cobos-Trigueros, M Rinaudo, M Solé, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 11, 2018
Current time-to-positivity of blood cultures in febrile neutropenia: a tool to be used in stewardship de-escalation strategiesP Puerta-Alcalde, C Cardozo, M Suárez-Lledó, et al.
Drug and Alcohol Dependence|December 12, 2018
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studiesGraham R Foster, Gregory J Dore, Stanley Wang, et al.
Gastroenterology|July 27, 2016
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated CirrhosisEdward Gane, Fred Poordad, Stanley Wang, et al.
Archivos De Bronconeumologia|June 12, 2003
[Second consensus report on the use of antimicrobial agents in exacerbations of chronic obstructive pulmonary disease]F Alvarez, E Bouza, J A García-Rodríguez, et al.
The Lancet. Gastroenterology & Hepatology|November 6, 2018
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trialTarik Asselah, Samuel S Lee, Betty B Yao, et al.
The New England Journal of Medicine|October 12, 2017
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal ImpairmentEdward Gane, Eric Lawitz, David Pugatch, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 11, 2019
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infectionEric Lawitz, Robert Flisiak, Manal Abunimeh, et al.
Pageof 26